Cationic surfactin liposomes for enhanced cellular delivery of siRNA

Asian Journal of Pharmaceutical Sciences

Volumn 4, Issue 4, 2009, Pages 207-214

  Shim, Ga Yong ^a   Kim, Sang Hee ^a   Han, Su Eun ^a   Kim, Young Bong ^b   Oh, Yu Kyoung ^c  

^a Korea University   (South Korea)

^b Konkuk University   (South Korea)

^c Seoul National University   (South Korea)

Author keywords

Biosurfactant; Cationic liposomes; SiRNA delivery; Surfactin

Indexed keywords

CATIONIC SURFACTANT; LIPOPLEX; LIPOSOME; LUCIFERASE; MESSENGER RNA; SMALL INTERFERING RNA; SURFACTIN; SURVIVIN;

ARTICLE; BIOCOMPATIBILITY; CANCER CELL; CELL ASSAY; CELL VIABILITY; COMPLEX FORMATION; CONTROLLED STUDY; DRUG FORMULATION; DRUG UPTAKE; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; FLUORESCENCE MICROSCOPY; GENE EXPRESSION; GENE TARGETING; HELA CELL; HUMAN; HUMAN CELL; LIPOSOMAL DELIVERY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ZETA POTENTIAL;

EID: 77953468076     PISSN: 18180876     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. K. Yamato, T. Yamada, M. Kizaki, et al. New highly potent and specific E6 and E7 siRNAs for treatment of HPV16 positive cervical cancer. Cancer Gene Ther., 2008, 15: 140-153.
2. N. Eter, T. U. Krohne, F. G. Holz. New pharmacologic approaches to therapy for age-related macular degeneration. BioDrugs 2006, 20: 167-179. (Pubitemid 43845337)
3. C. C. Lee, B. L. Chiang. RNA interference: new therapeutics in allergic diseases. Curr. Gene Ther. 2008, 8: 236-246.
4. N. Hokaiwado, F. Takeshita, A. Banas, et al. RNAi-based drug discovery and its application to therapeutics. IDrugs 2008, 11: 274-278. (Pubitemid 351481700)
5. A. R. de Fougerolles. Delivery vehicles for small interfering RNA in vivo. Hum. Gene Ther. 2008, 19: 125-132.
6. E. Z. Ron, E. Rosenberg. Natural roles of biosurfactants. Environ. Microbiol. 2001, 3: 229-236.
7. C. N. Mulligan. Environmental applications for biosurfactants. Environ. Pollut. 2005, 133: 183-198.
8. O. Bouffioux, A. Berquand, M. Eeman, et al. Molecular organization of surfactin-phospholipid monolayers: effect of phospholipid chain length and polar head. Biochim. Biophys. Acta. 2007, 1768: 1758-1768.
9. S. Y. Kim, J. Y. Kim, S. H. Kim, et al. Surfactin from Bacillus subtilis displays anti-proliferative effect via apoptosis induction, cell cycle arrest and survival signaling suppression. FEBS Lett. 2007, 581: 865-871.
10. M. Eeman, A. Berquand, Y. F. Dufrêne, et al. Penetration of surfactin into phospholipid monolayers: nanoscale interfacial organization. Langmuir, 2006, 22: 11337-11345.
11. N. Zaffaroni, M. Pennati, M. G. Daidone. Survivin as a target for new anticancer interventions. J. Cell Mol. Med. 2005, 9: 360-372.
12. M. Pennati, M. Folini, N. Zaffaroni. Targeting survivin in cancer therapy. Expert Opin. Ther. Targets. 2008, 12: 463-476.
13. H. N. Zhen, L. W. Li, W. Zhang, et al. Short hairpin RNA targeting survivin inhibits growth and angiogenesis of glioma U251 cells. Int. J. Oncol. 2007, 31: 1111-1117.
14. Q. X. Li, J. Zhao, J. Y. Liu, et al. Survivin stable knockdown by siRNA inhibits tumor cell growth and angiogenesis in breast and cervical cancers. Cancer Biol. Ther., 2006, 5: 860-866.
15. S. E. Han, H. Kang, G. Y. Shim, et al. Novel cationic cholesterol derivative-based liposomes for serum-enhanced delivery of siRNA. Int. J. Pharm. 2008, 353: 260-269.
16. S. E. Han, H. Kang, G. Y. Shim, et al. Cationic derivatives of biocompatible hyaluronic acids for delivery of siRNA and antisense oligonucleotides. J. Drug Target. 2009, 17: 123-132.